A practical reference on thymosin beta-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-07-22. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
=== In Anthropology === An anthropological lens challenges the idea that drug use is a universal problem, instead suggesting that perceptions of substance use and addiction depend on social, historical, political and cultural context. Drug policy and public responses vary globally, with disparities between the United Kingdom, Australia, and the United States. In the UK, drug use has become framed on crime prevention and coercion of drug users, demonstrating that definitions of harm are culturally and politically bound, questioning who health policies benefit. The USA has focused on the criminalisation of drug use, framing drug users as “morally reprehensible” and “deviant criminals”, shaping drug use as an issue of crime and social order. Australia’s 1985 adoption of harm minimisation strategies highlights that policy can shift alongside historical circumstances. The HIV/AIDS epidemic prompted a focus on safe injecting, rather than eradicating drug use. Maher and Dixon’s ethnographic research revealed that “attempts to suppress or control” drug use can shape how it is carried out, demonstrating that drug policy can shape experiences of harm. These cases corroborate Singer’s idea that drug use must be understood in its context, which challenges the narrative that drug-related harm is solely the users’ responsibility.
=== General ethical issues === If the creation of human DNA through artificial gene synthesis were to become technically feasible, several ethical and social issues have been identified by researchers. Scholars such as Adrian Villalba and Anna Smajdor have noted that synthetic DNA may challenge existing assumptions about the nature and significance of human genetic material. One area of concern involves the concept of genetic ownership. If a person’s DNA sequence can be artificially recreated in the laboratory, it becomes unclear who holds rights or control over the resulting material, and whether current legal and ethical frameworks are adequate to address such cases. There are also questions about identity. Human genomes have traditionally been viewed as closely linked to personal identity and biological heritage. However, the possibility of reconstructing or redesigning genomic sequences through synthetic DNA would significantly weaken this association. If genomes can be created, modified, or replicated independently of natural inheritance, the view that genetic makeup rigidly determines personal traits becomes increasingly difficult to sustain. In this context, synthetic DNA is proposed as effectively undermining genetic determinism and prompting a re-evaluation of assumptions about the role of genes in shaping individual identity. Privacy is another significant issue. The possibility of synthesizing sequences identical or similar to those of existing individuals raises concerns about genetic data protection and potential misuse.
== Frequency of use == Oxazepam, along with diazepam, nitrazepam, and temazepam, were the four benzodiazepines listed on the pharmaceutical benefits scheme and represented 82% of the benzodiazepine prescriptions in Australia in 1990–1991. It is in several countries the benzodiazepine of choice for novice users, due to a low chance of accumulation and a relatively slow absorption speed.
Sources: en.wikipedia.org
The uvula (pl.: uvulas or uvulae), also known as the palatine uvula or staphyle, is a conic projection from the back edge of the middle of the soft palate, composed of connective tissue containing a number of racemose glands, and some muscular fibers. It also contains many serous glands, which produce thin saliva. While historically believed that only humans have a uvula, the same structure has been found in miniature pigs.
=== Glycogen depletion and endurance exercise === Long-distance athletes, such as marathon runners, cross-country skiers, and cyclists, often experience glycogen depletion, where almost all of the athlete's glycogen stores are depleted after long periods of exertion without sufficient carbohydrate consumption. This phenomenon is referred to as "hitting the wall" in running and "bonking" in cycling. Glycogen depletion can be forestalled in three possible ways:
The growth of bacteria in laboratory cultures is the mainstay method used by bacteriologists. Both solid and liquid culture media are used. Solid culture medium is usually nutrient agar in a petri dish. The constituents of the nutrient agar vary according to the bacteria under investigation. For growing the bacterium Haemophilus influenzae, for example, which is dependent on hemin and nicotinamide adenine dinucleotide for its growth, blood (usually from a sheep or a horse) is added to the medium. When growing bacteria that are found in the intestines of mammals, such as salmonella, XLD agar which contains, among other ingredients deoxycholic acid is used.
Sources: en.wikipedia.org
The abolition of the ILEA meant that Inner London boroughs had to, among other things, establish their own admissions policies. This indirectly impacted school admissions across the country, because the Greenwich judgment of 1989 established that LEAs could no longer give their own residents priority access to schools.
=== Occupational diseases === Men are more likely to be employed in positions with higher exposure to occupational health hazards. They account for two-thirds of occupational diseases leading to permanent disability. Deaths from occupational disease are over 80 times more common among men than women.
On 11 August, Lula and ministers unveiled a new Growth Acceleration Programme, according to the proposal, an estimated 1.7 trillion reais (worth around US$350 billion at the time) will be spent over the following 4 years. Of this, 610 billion is expected to be spent on slum urbanisation programmes, including the development of housing, public transport, sanitation, energy and protection from natural disasters, this includes further investments on social infrastructure programmes such as Minha Casa, Minha Vida, Luz Para Todos and Água Para Todos, as well as creation and expansion of ports, airports, motorways and railways. 540 billion is expected to be spent on expanding the electric grid and petrochemical industries, with 80% of the newly developed electric production capacity being expected to come from renewable sources; 349 billion is expected to be spent on transportation infrastructure, including for motor vehicles, trains, marine vehicles, and aeroplanes. Lula also announced the construction of the "West-East Integration Railway (FIOL)" as the first project of the programme, which will connect the southwest of Bahia to the coast of southern Bahia. Other areas of investment include "digital inclusion and connectivity" (expansion of 4G and 5G networks and digital education), healthcare (construction of new basic health units and maternities, as well purchase of ambulances and vaccines), education (construction, expansion and modernization of day care centers, full-time schools and federal institutes and universities) and defence infrastructure.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.